Shawn Flanagan

Shawn Flanagan has a strong background in clinical pharmacology and early development. Shawn has held various leadership roles in several pharmaceutical companies, including Cidara Therapeutics, Esperion Therapeutics, Merck, Cubist, Trius Therapeutics, Orexigen Therapeutics, Amylin Pharmaceuticals, Ligand Pharmaceuticals, Eli Lilly, and Pharmetrix Corporation.

At Cidara Therapeutics, Shawn currently serves as the Vice President of Clinical Pharmacology & Early Development. Prior to this role, they were the Executive Director of Clinical Pharmacology at Esperion Therapeutics.

Shawn's experience in clinical pharmacology began at Pharmetrix Corporation, where they worked as an Associate Scientist and served as a project technical leader. Shawn then moved to Eli Lilly as a Senior Pharmacologist in Drug Disposition, where they designed and conducted studies on drug candidates and led a team in toxicology and ADME.

Shawn later joined Ligand Pharmaceuticals as a Senior Research Scientist in Clinical PK, overseeing the design, implementation, and reporting of PK, metabolism, and bioanalytical studies. At Amylin Pharmaceuticals, Shawn served as the Director of PKDM, providing leadership in PK, TK, and ADME support for peptide and protein therapeutics.

Shawn also worked at Orexigen Therapeutics as a Senior Director of Clinical Pharmacology and was responsible for all aspects of Biopharmaceutical, Clinical Pharmacology, and Pharmacokinetic studies for CONTRAVE. Shawn played a key role in regulatory interactions for this complex product.

At Trius Therapeutics and Cubist, which merged in 2013, Shawn served as the Executive Director and Senior Director of Clinical Pharmacology, respectively. Shawn led studies in both companies to differentiate existing products using toxicology, pharmacology, and clinical pharmacology approaches.

During their time at Merck, Shawn held the position of Senior Principal Scientist. Shawn played a crucial role in designing and overseeing clinical pharmacokinetic studies, developing modeling analysis plans, and preparing regulatory submissions for anti-infective projects.

Overall, Shawn Flanagan's work experience showcases their expertise in clinical pharmacology, PK/ADME, regulatory submissions, and leadership in the pharmaceutical industry.

Shawn Flanagan obtained a PhD in Pharmaceutical Chemistry and Pharmaceutics from the University of California, San Francisco, where they attended from 1995 to 1999.